What makes the α1A -adrenoceptor gene product assume an α1L -adrenoceptor phenotype?

Carl W White, Edilson Dantas da Silva Junior, Linzi Lim, Sabatino Ventura

British journal of pharmacology 2019 Jul

filter terms:

The α1A -adrenoceptor is abundantly expressed in the lower urinary tract and is the principal therapeutic target for the symptomatic treatment of lower urinary tract symptoms in men. Prazosin has a lower affinity for the lower urinary tract α1A -adrenoceptor than α1A -adrenoceptors found in other parts of the body. This has led to the lower urinary tract α1A -adrenoceptor being subclassified as an α1L -adrenoceptor. It was demonstrated that this pharmacologically distinct α1L -adrenoceptor is a product of the α1A -adrenoceptor gene, but the mechanism by which this altered phenotype is achieved remains a mystery. Hypotheses for this altered pharmacology include the presence of an interacting protein such as cysteine-rich with EGF-like domain (CRELD) 1 or other GPCRs such as the CXCR2 chemokine or 5-HT1B receptor. Alternatively, the influence of breast cancer resistance protein (BCRP) efflux transporters on the pharmacology of α1A -adrenoceptors has also been investigated. These and other hypotheses will be described and discussed in this review. LINKED ARTICLES: This article is part of a themed section on Adrenoceptors-New Roles for Old Players. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.14/issuetoc. © 2019 The British Pharmacological Society.

Citation

Carl W White, Edilson Dantas da Silva Junior, Linzi Lim, Sabatino Ventura. What makes the α1A -adrenoceptor gene product assume an α1L -adrenoceptor phenotype? British journal of pharmacology. 2019 Jul;176(14):2358-2365